Cargando…

Identification of a New Selective Chemical Inhibitor of Mutant Isocitrate Dehydrogenase-1

BACKGROUND: Recent genome-wide sequencing studies have identified unexpected genetic alterations in cancer. In particular, missense mutations in isocitrate dehydrogenase-1 (IDH1) at arginine 132, mostly substituted into histidine (IDH1-R132H) were observed to frequently occur in glioma patients. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyo-Joon, Choi, Bu Young, Keum, Young-Sam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Cancer Prevention 2015
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4384718/ https://www.ncbi.nlm.nih.gov/pubmed/25853107 http://dx.doi.org/10.15430/JCP.2015.20.1.78

Ejemplares similares

Isocitrate dehydrogenase mutations: new opportunities for translational research
por: Keum, Young-Sam, et al.
Publicado: (2015)

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
por: Golub, Danielle, et al.
Publicado: (2019)

Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis
por: OHBA, Shigeo, et al.
Publicado: (2016)

Adult isocitrate dehydrogenase–mutant brainstem glioma: illustrative case
por: Ye, Vincent C., et al.
Publicado: (2021)

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma
por: Gallus, Marco, et al.
Publicado: (2023)

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
por: Liu, Xiaoyan, et al.
Publicado: (2019)

Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays
por: Urban, Daniel J., et al.
Publicado: (2017)

Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat
por: Chang, Chi-Ming, et al.
Publicado: (2023)

Differentiating Inhibition Selectivity and Binding Affinity of Isocitrate Dehydrogenase 1 Variant Inhibitors
por: Liu, Shuang, et al.
Publicado: (2023)

Identification of medicinal compounds as potential inhibitors for mutated isocitrate dehydrogenases against chondrosarcoma
por: Shah, Fahad Hassan, et al.
Publicado: (2022)

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer
por: Liu, Yang, et al.
Publicado: (2023)

Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors
por: Reinbold, Raphael, et al.
Publicado: (2022)

Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas
por: Kim, Ja Eun, et al.
Publicado: (2015)

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
por: DiNardo, Courtney D., et al.
Publicado: (2021)

Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases: Synthesis, Structure–Activity Relationship, and Selective Antitumor Activity
por: Liu, Zhen, et al.
Publicado: (2014)

Gemistocytic Differentiation in Isocitrate Dehydrogenase Mutant Astrocytomas: A Histopathological and Survival Analysis
por: Hassan, Usman, et al.
Publicado: (2023)

Vorasidenib: A promising therapeutic breakthrough for diffuse isocitrate dehydrogenase mutant gliomas
por: Wahid, Abdul, et al.
Publicado: (2023)

Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)

Ethanol Extract of Cirsium japonicum var. ussuriense Kitamura Exhibits the Activation of Nuclear Factor Erythroid 2-Related Factor 2-dependent Antioxidant Response Element and Protects Human Keratinocyte HaCaT Cells Against Oxidative DNA Damage
por: Yoo, Ok-Kyung, et al.
Publicado: (2016)

Isocitrate dehydrogenase mutations in myeloid malignancies
por: Medeiros, B C, et al.
Publicado: (2017)

Potential Mitochondrial Isocitrate Dehydrogenase R140Q Mutant Inhibitor from Traditional Chinese Medicine against Cancers
por: Lee, Wen-Yuan, et al.
Publicado: (2014)

Rational Computational Approaches in Drug Discovery: Potential Inhibitors for Allosteric Regulation of Mutant Isocitrate Dehydrogenase-1 Enzyme in Cancers
por: Thamim, Masthan, et al.
Publicado: (2023)

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism
por: Su, Li, et al.
Publicado: (2020)

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
por: Mellinghoff, Ingo K., et al.
Publicado: (2020)

Photoactivation of Mutant Isocitrate Dehydrogenase 2 Reveals Rapid Cancer-Associated Metabolic and Epigenetic Changes
por: Walker, Olivia S., et al.
Publicado: (2016)

Oncogenic transgelin-2 is differentially regulated in isocitrate dehydrogenase wild-type vs. mutant gliomas
por: Beyer, Sasha J., et al.
Publicado: (2018)

Mutants for Drosophila Isocitrate Dehydrogenase 3b Are Defective in Mitochondrial Function and Larval Cell Death
por: Duncan, Dianne M., et al.
Publicado: (2017)

Prognostic value of O(6)-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas
por: Lam, Keng, et al.
Publicado: (2022)

Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents
por: Khalil, Ahmed F., et al.
Publicado: (2023)

The Role of Isocitrate Dehydrogenases in Direct Reprogramming to Cardiomyocytes
por: Ishida, Tomoaki, et al.
Publicado: (2021)

Roles of metal ions in the selective inhibition of oncogenic variants of isocitrate dehydrogenase 1
por: Liu, Shuang, et al.
Publicado: (2021)

Hub gene identification and prognostic model construction for isocitrate dehydrogenase mutation in glioma
por: Jia, Yanfei, et al.
Publicado: (2020)

Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma
por: Lang, Fengchao, et al.
Publicado: (2021)

Identification of a new mutation in the human xanthine dehydrogenase responsible for xanthinuria type I
por: Collazo Abal, Cristina, et al.
Publicado: (2021)

5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma
por: Glowacka, Wioletta K., et al.
Publicado: (2018)

Combined Treatment With Radiotherapy and Immunotherapy for Isocitrate Dehydrogenase Mutant Brainstem Glioma in Adult: A Case Report
por: Morimoto, Takayuki, et al.
Publicado: (2022)

Erratum to: Prognostic value of O(6)-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas
Publicado: (2022)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Importance of Age and Noncontrast-Enhancing Tumor as Biomarkers for Isocitrate Dehydrogenase–Mutant Glioblastoma: A Multicenter Study
por: Uetani, Hiroyuki, et al.
Publicado: (2023)

Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants
por: Gao, Mingzhao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vgg0vnrrubq2f2f00772rvf5m4